A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
OBJECTIVE
The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.


METHODS
PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m(2) was given to the first 11 patients and was reduced to 560 mg/m(2) for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients.


RESULTS
Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia.


CONCLUSIONS
PZA at the dose and schedule employed, has insignificant activity in this population.
Plaxe
Steven C
SC
Department of Reproductive Medicine, Medical Center, University of California, San Diego, 402 Dickinson Street, San Diego, CA 92103-8433, USA.
Blessing
John A
JA
Olt
George
G
Husseinzadah
Nader
N
Lentz
Samuel S
SS
DeGeest
Koen
K
Valea
Fidel A
FA
D000166:Acridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007364:Intercalating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016879:Salvage Therapy; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014839:Vomiting / Q000139:chemically induced
D000166:Acridines; D004791:Enzyme Inhibitors; D007364:Intercalating Agents; D019384:Nucleic Acid Synthesis Inhibitors; D011720:Pyrazoles; C064541:NSC 366140